Notice NOT-DA-24-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-294 from the NIH Guide for Grants and Contracts. Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Funding Opportunity PAR-24-293 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Notice NOT-NR-25-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-061 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from eligible academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education, as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence(IEE) in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity from either research-intensive or low-resourced institutions. The goal of this NOFO is to modernize biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to produce substantial long-term improvements to the institutional research infrastructure. Intended projects are the construction or modernization of core facilities and the development of other shared research infrastructure serving an institution-wide research community with broad impact on biomedical research.

Notice NOT-GM-24-055 from the NIH Guide for Grants and Contracts

Notice NOT-NR-24-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-178 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-26-010 from the NIH Guide for Grants and Contracts. To promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction.

Funding Opportunity RFA-DA-26-009 from the NIH Guide for Grants and Contracts. To promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction.

Notice NOT-TR-24-031 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-031 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-033 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-24-036 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to establish a Cancer Immunoprevention Network (CIP-Net) Data and Resource Coordinating Center (CIP-Net DRCC). The overall goals of this NOFO and the companion NOFO (RFA-CA-23-029, Cancer Immunoprevention Network (CIP-Net) Research Projects (UG3/UH3 Clinical Trials Not Allowed)) are to establish an agile and effective network to undertake collaborative research focusing on cancer immunoprevention research. The CIP-Net DRCC will provide overall data and resource coordination, support, and facilitate collaboration across CIP-Net. The CIP-Net DRCC will provide bioinformatic and analytical support, enhance immunoprevention research awareness through scientific communications and meetings, conduct scientific outreach to build immunoprevention bridges across complementary cancer research communities, and foster early career scientist career development.

Notice NOT-HS-24-026 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-26-120 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this NOFO will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the use of new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.

Funding Opportunity RFA-NS-25-024 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.

Funding Opportunity RFA-DK-25-022 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for Recruitment Sites (RS) to enroll adult and/or pediatric patients with Type 1 diabetes (T1D) with, or at high risk of, diabetic nephropathy into a longitudinal cohort study and perform protocol-based research kidney biopsies. These T1D RS will leverage the existing resources of the Kidney Precision Medicine Project (KPMP). T1D RS will collaborate directly with the KPMP to obtain and evaluate kidney biopsies from participants, create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies. Current KPMP RS are not eligible to apply.

Notice NOT-DE-25-038 from the NIH Guide for Grants and Contracts